Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depression and analgesia.
For use during the induction and maintenance of general anesthesia.
the Affiliated Hospital of Yangzhou University, Yangzhou, Jiangsu, China
Wonkwag UH, Iksan, Korea, Republic of
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
ICU, Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China
CHIREC Delta Hospital, Brussels, Belgium
Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
Anhui Provincial Hospital, Hefei, Anhui, China
Amiens Univesrity Hospital, Amiens, France
Rouen University Hospital, Rouen, France, Normandy, France
Lille Hopistal University, Lille, France
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
University Medical Center Groningen, Groningen, Netherlands
Gangnam Severance Hospital, Seoul, Korea, Republic of
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.